Exploration of Targeted Anti-tumor Therapy is a peer-reviewed english-language open-access journal published by Open Exploration Publishing Inc. in China, operating under an open-access model since 2020. The journal covers Internal medicine.
Authors are required to pay an article processing charge to publish in Exploration of Targeted Anti-tumor Therapy; refer to the journal's APC page for the current rate. A waiver policy is offered for eligible authors. Articles are released under the CC BY, Publisher's own license license (see other journals using this license).
To date, Exploration of Targeted Anti-tumor Therapy has published 363 articles. Articles are minted with DOIs through the prefix 10.37349. All submissions undergo plagiarism screening before peer review.
Keywords
cancer, target therapy, precision oncology, diagnosis, biomarkers, cancer mechanisms
At a glance
- Publisher
- Open Exploration Publishing Inc.
- Country
- China
- Primary language
- English
- License
- CC BY, Publisher's own license
- Peer review
- Anonymous peer review
- OA since
- 2020
- Review time
- 13 weeks
- DOI prefix
10.37349- Plagiarism check
- Yes
ISSN
- electronic
- 2692-3114
Frequently asked questions
Is Exploration of Targeted Anti-tumor Therapy peer-reviewed?
Does Exploration of Targeted Anti-tumor Therapy charge an article processing charge (APC)?
What subjects does Exploration of Targeted Anti-tumor Therapy publish?
What languages does Exploration of Targeted Anti-tumor Therapy accept?
What is the ISSN of Exploration of Targeted Anti-tumor Therapy?
2692-3114 (electronic).